| Name | Title | Contact Details |
|---|
ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCA Pharma is a leading FDA 503B outsourcing facility delivering the highest quality sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. SCA Pharma prides itself on being the most customer- and patient-focused 503B in the industry. Known for its unwavering quality and high-touch customer service, SCA Pharma is headquartered in Little Rock, AR with a sister facility in Windsor, CT. The Windsor facility boasts more than 90,000 square feet of sterile compounding laboratory and manufacturing space while Little Rock is home to SCA Pharma`s 17,000 square foot sterile compounding facility. Both facilities meet or exceed FDA cGMP manufacturing guidelines. SCA Pharma employs more than 500 people across both facilities, as well as a team of sales representatives across the country.
vTv Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.